Zobrazeno 1 - 10
of 17
pro vyhledávání: '"V N Amirjanova"'
Autor:
A E Karateev, E Yu Pogozheva, E A Filatova, V N Amirjanova, A M Lila, O V Antipova, A R Babaeva, A V Volkorezova, A F Davydova, V G Davtyan, E V Zonova, O N Ivanova, N N Kalinina, N I Kiseleva, L A Knyazeva, A I Kulikov, O B Nesmeyanova, V I Mazurov, L V Masneva, L V Menshikova, I V Obuhova, E N Otteva, T S Salnikova, I N Shchendrygin, S P Yakupova
Publikováno v:
Терапевтический архив, Vol 90, Iss 6, Pp 65-73 (2018)
Non-steroidal anti-inflammatory drugs (NSAIDs) are most popular medications for the treatment of pain in common musculoskeletal diseases such as osteoarthritis (OA) and non-specific low back pain (LBP). However, the factors affecting the effectivenes
Externí odkaz:
https://doaj.org/article/e4a273b8b13b4eb68d62beba2d567eb5
Autor:
E. L. Nasonov, V. N. Amirjanova, Y. A. Olyunin, Y. V. Muravyev, A. A. Baranov, E. V. Zonova, E. N. Otteva, A. I. Zagrebneva, D. I. Abdulganieva, P. I. Pchelnikova
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 4, Pp 435-449 (2023)
Rheumatoid arthritis (RA) is the most frequent immunoinflammatory (autoimmune) rheumatic disease characterized by chronic erosive arthritis and systemic damage to internal organs. The data obtained in the course of basic research on deciphering the m
Externí odkaz:
https://doaj.org/article/622d326a6fcc4ceba244273a93e899a0
Autor:
V. N. Amirjanova, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 4, Pp 430-433 (2023)
Externí odkaz:
https://doaj.org/article/c3129a12a2f84b7cbd9099566cecab18
Autor:
V. N. Amirjanova, M. A. Makarov, A. E. Karateev, A. E. Khramov, S. V. Maglevaniy, A. V. Rozov, V. A. Nesterenko, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 3, Pp 260-267 (2023)
The article presents updated guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons on the perioperative treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ar
Externí odkaz:
https://doaj.org/article/300ac084419e420f90c7ce27639e117e
Autor:
E. Yu. Polishchuk, A. E. Karateev, A. S. Potapova, E. S. Filatova, V. N. Khlaboshchina, V. N. Amirjanova, A. M. Lila
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 3, Pp 361-368 (2023)
Achieving a good treatment outcome in rheumatic diseases (RD) requires regular, dynamic patient monitoring and therapy correction if it is not effective or intolerant. The patient assessment must be based on clear criteria to objectify the main manif
Externí odkaz:
https://doaj.org/article/25ff584d82ee4e8488c7309bba902b56
Autor:
A. S. Potapova, A. E. Karateev, E. Yu. Polishchuk, E. V. Matyanova, T. S. Panevin, A. S. Semashko, A. O. Bobkova, A. R. Khalmetova, E. S. Filatova, V. N. Amirjanova, A. M. Lila
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 2, Pp 214-219 (2023)
Central sensitization (CS) is a condition characterised by (associated with) neuroplastic changes in nociceptive neurons, sub-threshold afferent input, pain hypersensitivity and development widespread pain. Insufficient response to disease-modifying
Externí odkaz:
https://doaj.org/article/74645b093ce24a3d8d700870329a9f0f
Autor:
A. E. Karateev, A. M. Lila, T. S. Panevin, A. S. Potapova, A. S. Semashko, A. O. Bobkova, V. N. Amirjanova, E. G. Zotkin
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 4, Pp 427-437 (2022)
One of the main tasks of modern complex therapy of rheumatoid arthritis (RA) is to improve the quality of life of patients. To do this, it is necessary not only to achieve remission or low activity, but also to successfully control the main, most pai
Externí odkaz:
https://doaj.org/article/b5728cd6ac36424692e931a34fee9b02
Autor:
V. N. Amirjanova, A. E. Karateev, E. Yu. Pogozheva, E. S. Filatova, R. R. Samigullina, V. I. Mazurov, O. N. Anoshenkova, N. A. Lapkina, A. A. Baranov, T. Yu. Grineva, A. M. Lila, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 3, Pp 327-333 (2022)
The aim of the study was to evaluate the effectiveness of UPA in RA patients in real clinical practice after 3 and 6 months of therapy.Material and methods. The study included 63 RA patients with high activity of the disease. Activity was assessed ac
Externí odkaz:
https://doaj.org/article/5cc72e5d8cab4c76b31da0460442ceb8
Autor:
A. E. Karateev, E. Yu. Polishchuk, A. S. Potapova, E. V. Matyanova, A. S. Semashko, А. O. Bobkova, E. S. Filatova, V. N. Amirjanova, S. I. Glukhova, E. G. Zotkin, A. M. Lila
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 2, Pp 149-156 (2022)
The prescribing of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (iJAK) during the COVID-19 pandemic requires a balanced approach and tight monitoring of the patients.The aim of the study was to study the effe
Externí odkaz:
https://doaj.org/article/dc6a09e7a01c413fb5ef3e047fee5693
Autor:
V. N. Amirjanova, A. E. Karateev, E. Y. Pogozheva, A. A. Baranov, V. I. Mazurov, R. R. Samigullina, O. N. Anoshenkova, N. A. Lapkina, T. Yu. Grineva, E. L. Nasonov, A. M. Lila
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 5, Pp 571-577 (2021)
Upadacitinib (UPA), a JAK inhibitor, is a new therapeutic option that allows patients with insufficient response to therapy with basic anti-inflammatory drugs (DMARDs) or genetically engineered biological drugs (GEBDs) to achieve the goals of therapy
Externí odkaz:
https://doaj.org/article/0bc3bbda0ae94c719d017afb5e5ce707